SWOT Analysis for Alivus Life Sciences Ltd.

Add SWOT widget to your site/app

Companies with no Debt
Benjamin Graham Value Screen
PEG lower than Industry PEG
Growth in Quarterly Net Profit with increasing Profit Margin (YoY)
Annual Net Profits improving for last 2 years
Book Value per share Improving for last 2 years
Companies with Zero Promoter Pledge
Rising Delivery Percentage Compared to Previous Day and Month, Strong Volumes
Volume Shockers

Companies with no Debt

Benjamin Graham Value Screen

PEG lower than Industry PEG

Growth in Quarterly Net Profit with increasing Profit Margin (YoY)

Annual Net Profits improving for last 2 years

Book Value per share Improving for last 2 years

Companies with Zero Promoter Pledge

Rising Delivery Percentage Compared to Previous Day and Month, Strong Volumes

Volume Shockers

Promoter decreasing their shareholding
Bearish Stocks - Stocks with Medium to Low Trendlyne Momentum Score
Stocks with Expensive Valuations according to the Trendlyne Valuation Score
Inefficient use of capital to generate profits - RoCE declining in the last 2 years
Inefficient use of shareholder funds - ROE declining in the last 2 years
Inefficient use of assets to generate profits - ROA declining in the last 2 years
Declining Net Cash Flow : Companies not able to generate net cash
Weak Momentum: Price below Short, Medium and Long Term Averages
Degrowth in Revenue, Profits and Operating Profit Margin in recent results (QoQ)
RSI indicating price weakness
Top Losers
Near 52 Week Low
Stocks Underperforming their Industry Price Change in the Quarter

Promoter decreasing their shareholding

Bearish Stocks - Stocks with Medium to Low Trendlyne Momentum Score

Stocks with Expensive Valuations according to the Trendlyne Valuation Score

Inefficient use of capital to generate profits - RoCE declining in the last 2 years

Inefficient use of shareholder funds - ROE declining in the last 2 years

Inefficient use of assets to generate profits - ROA declining in the last 2 years

Declining Net Cash Flow : Companies not able to generate net cash

Weak Momentum: Price below Short, Medium and Long Term Averages

Degrowth in Revenue, Profits and Operating Profit Margin in recent results (QoQ)

RSI indicating price weakness

Top Losers

Near 52 Week Low

Stocks Underperforming their Industry Price Change in the Quarter

Mutual Funds Increased Shareholding in Past Month
FII / FPI or Institutions increasing their shareholding
MFs increased their shareholding last quarter
Mutual Funds Increased Shareholding over the Past Two Months
Mf buying for 2 months

Mutual Funds Increased Shareholding in Past Month

FII / FPI or Institutions increasing their shareholding

MFs increased their shareholding last quarter

Mutual Funds Increased Shareholding over the Past Two Months

Mf buying for 2 months

Big Deal (Insider and SAST) sells last month greater than 1% of total shares
Companies with high market cap, lower public shareholding
Red Flags: Weakening Technicals and Share Price Decline
Insiders sold stocks

Big Deal (Insider and SAST) sells last month greater than 1% of total shares

Companies with high market cap, lower public shareholding

Red Flags: Weakening Technicals and Share Price Decline

Insiders sold stocks

Rising Delivery Percentage Compared to Prev Day
Rising Delivery Percentage Compared to Previous Day and Month, Strong Volumes
Bullish or Bearish Candlestick Strength - Indices
Average Financial Performers - Stocks with Medium Trendlyne Durability Score versus Benchmarks
Decline in Net Profit with falling Profit Margin (QoQ)

Rising Delivery Percentage Compared to Prev Day

Rising Delivery Percentage Compared to Previous Day and Month, Strong Volumes

Bullish or Bearish Candlestick Strength - Indices

Average Financial Performers - Stocks with Medium Trendlyne Durability Score versus Benchmarks

Decline in Net Profit with falling Profit Margin (QoQ)

Alivus Life Sciences Ltd. SWOT Analysis: Strengths, Weakness, Opportunity, and Threats

Alivus Life Sciences Ltd. has 9 Strengths, 13 Weaknesses, 5 Opportunities and 4 Threats. The SWOT product gives you a quick x-ray of a stock's outlook and potential

Companies with no Debt

Benjamin Graham Value Screen

PEG lower than Industry PEG

Growth in Quarterly Net Profit with increasing Profit Margin (YoY)

Annual Net Profits improving for last 2 years

Book Value per share Improving for last 2 years

Companies with Zero Promoter Pledge

Rising Delivery Percentage Compared to Previous Day and Month, Strong Volumes

Volume Shockers

Promoter decreasing their shareholding

Bearish Stocks - Stocks with Medium to Low Trendlyne Momentum Score

Stocks with Expensive Valuations according to the Trendlyne Valuation Score

Inefficient use of capital to generate profits - RoCE declining in the last 2 years

Inefficient use of shareholder funds - ROE declining in the last 2 years

Inefficient use of assets to generate profits - ROA declining in the last 2 years

Declining Net Cash Flow : Companies not able to generate net cash

Weak Momentum: Price below Short, Medium and Long Term Averages

Degrowth in Revenue, Profits and Operating Profit Margin in recent results (QoQ)

RSI indicating price weakness

Top Losers

Near 52 Week Low

Stocks Underperforming their Industry Price Change in the Quarter

Mutual Funds Increased Shareholding in Past Month

FII / FPI or Institutions increasing their shareholding

MFs increased their shareholding last quarter

Mutual Funds Increased Shareholding over the Past Two Months

Mf buying for 2 months

Big Deal (Insider and SAST) sells last month greater than 1% of total shares

Companies with high market cap, lower public shareholding

Red Flags: Weakening Technicals and Share Price Decline

Insiders sold stocks

Rising Delivery Percentage Compared to Prev Day

Rising Delivery Percentage Compared to Previous Day and Month, Strong Volumes

Bullish or Bearish Candlestick Strength - Indices

Average Financial Performers - Stocks with Medium Trendlyne Durability Score versus Benchmarks

Decline in Net Profit with falling Profit Margin (QoQ)